Affymetrix Shares Fall on Analyst Downgrade | GenomeWeb

NEW YORK (GenomeWeb News) – Shares in Affymetrix plummeted more than 13 percent in afternoon trading today on Nasdaq after an analyst from Barclay's Capital downgraded the firm from "equal weight" to "underweight."

Shares of Affymetrix were trading at $5.58 this afternoon, a decrease of $0.86 from yesterday's closing price of $6.44.

The Barclay's analyst downgraded Affymetrix's stock based on the recent introduction of competing technologies that are rendering Affymetrix's products "obsolete."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.